PFS Foundation News

Finasteride-Induced Suicides up 8.4% in WHO’s VigiBase

SOMERSET, N.J., July 13, 2016 – Reports of finasteride-induced completed suicides are up 8.4% in the World Health Organization Progamme for International Drug Monitoring’s database of adverse drug reactions (ADRs) for Q1 through Q2 2016 over Q4 2015. The absolute number of completed suicides rose from 59 to 64 within that period.  Also in the […]

PFS Foundation Web Traffic Up 33% Year Over Year

SOMERSET, N.J., Jan. 5, 2016 – Traffic to the PFS Foundation website rose 33.6 percent in 2015, compared to 2014, according to Google Analytics. Concurrently, users in 161 countries—or 82.5 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed information on the condition via PFSFoundation.org in 2015, […]

Reminder: Report PFS Symptoms to National Pharmacovigilance Authorities

SOMERSET, N.J., Sept. 9, 2015 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to their respective national pharmacovigilance authorities for inclusion in the World Health Organization Progamme for International Drug Monitoring’s VigiBase database for adverse drug reactions (ADRs). Run by Uppsala Monitoring Centre (UMC), which provides scientific leadership […]

Data Available on Adverse Side Effects of 5α-RIs Don’t Conclusively Suggest They’re Safe, Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Sept. 7, 2015 – Data from preclinical and clinical studies have provided substantial evidence that 5α-Reductase inhibitors (5α-RIs) such as finasteride and dutasteride cause loss or reduction of libido, increase the risk of erectile dysfunction and ejaculatory dysfunction, and may contribute to the onset of depression. These agents interfere with the biosynthesis and […]

Suggestion That Sexual Side Effects Appear Early in Finasteride Therapy then Return to Normal is ‘Inaccurate,’ Say Researchers at Boston University School of Medicine

SOMERSET, N.J., Aug. 26, 2015 – Twenty-five percent of men currently taking finasteride or dutasteride (brand names Proscar and Avodart) for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss are also at risk for adverse events elicited by […]

2015 PFS Foundation Annual Address

Aug. 4, 2015 Dear Friends: By many accounts, we’ve reached a tipping point on post-finasteride syndrome awareness within the medical community. The most significant advancement occurred in March, when the U.S. National Institutes of Health added PFS to its Genetic and Rare Diseases Information Center. “Studies are under way to understand the safety profile of […]

Southwest Brain Bank Launches PFS Brain and Spinal Cord Donation Program

SOMERSET, N.J., July 15, 2015 – The Southwest Brain Bank (SWBB) in the Department of Psychiatry at the University of Texas Health Science Center in San Antonio has received its first donation of the brain and spinal cord of a post-finasteride syndrome (PFS) patient and formed a program to collect and study post-mortem human brain […]

U.S. National Institutes of Health Adds PFS to Genetic and Rare Diseases Info Center

May 19, 2015 Dear Public Health Official: The U.S. National Institutes of Health recently added post-finasteride syndrome (PFS) to its Genetic and Rare Diseases Information Center, noting that: “Studies are underway to understand the safety profile of 5-alpha reductase inhibitor drugs with respect to adverse events…and their permanency.” This federal listing of PFS comes in […]